Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “One of the great movements in my lifetime among educated people is the need to commit themselves to action. Most people are not satisfied with giving money; we also feel we need to work.”

    — Peter Drucker

Brain Tumor News

Report analyses the Brain Tumor Diagnosis And Therapeutics market By Type, By Applicatio, assesses the market By Region (Europe, Asia Pacific, North America, Rest of the world) and By Country (United Kingdom, Germany, U.S., Canada, Mexico, Japan, India, France, China, Australia), assesses the market for the historical period of 2014-2018 and the forecast period of 2019-2024.

A new drug, known as IP1867B, could be used for future treatments of brain tumors. The research team showed that IP1867B worked with existing cancer treatments boosting their effectiveness and, in some cases, restored sensitivity to some treatments.

Forrest General became the first hospital in Mississippi to use Gleolan™ (aminolevulinic acid HCl) for enhanced visualization of high-grade gliomas (including glioblastomas), or tumors occurring in the glial cells of the brain. This solution causes tumor cells to glow red under blue light allowing the neurosurgeon to remove as much of the tumor as possible without affecting healthy brain cells.

An international team led by researchers has discovered the energy production mechanism of cancerous cells that drives the growth of the nucleolus and causes tumors to rapidly multiply. The findings could lead to the development of new cancer treatments that would stop tumor growth by cutting the energy supply to the nucleolus.

Massachusetts General Hospital (MGH) investigators have created a new method that could make immune therapy more effective again brain tumors and expand its use against other types of solid tumors.

The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered class of targeted therapy that undermines cancer cell division and could form the backbone of a new drug cocktail for patients with malignant brain tumors like glioblastoma.

View Previous News Articles - Click Here!